Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease

StatusCompleted
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 6 more changesShow less
    • Final enrollment: 7 participants (planned 18)
    • Primary completion date changed from estimate of Aug 2026 to Jun 25, 2026
    • Eligibility criteria expanded, about 19 words
    • Secondary endpoints: details revised at 2 of 2 entries
    • Site details revised
    • Publications: details revised at 1 of 1 entry
  2. Primary completion date: Feb 2025 to Aug 2026
    • Study completion date: Mar 2025 to Aug 2026
    v7
  3. Secondary endpoints: details revised at 1 of 2 entriesv6
  4. Study title expanded, about 8 wordsv5
  5. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Dec 2024 to Feb 2025
    • Study completion date: Jan 2025 to Mar 2025
    • Start date changed from estimate of Jun 2023 to Aug 14, 2023
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Start date: Apr 2023 to Jun 2023
    • Primary completion date: Oct 2024 to Dec 2024
    • Study completion date: Nov 2024 to Jan 2025
    v3
  2. Start date: Jan 2023 to Apr 2023
    • Primary completion date: Jul 2024 to Oct 2024
    • Study completion date: Aug 2024 to Nov 2024
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a research study to evaluate the safety of an investigational autologous cell product obtained from participant's own adipose tissue as a possible treatment for Alzheimer disease.
Trial Details
NCT Number NCT05667649
Lead Sponsor Regeneration Biomedical, Inc.
Conditions
(from sponsor)		 Alzheimer Disease
Related terms Alzheimer Disease
Enrollment 7 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov